None listed
Conditions
Interventions
ferrous sulfate
Type of group
A concentration of elemental iron of 15 mg in 0.6 ml of a calibrated dropper is administered.
Group name:FERRIC POLYMALTHOSATE Type of group
A concentration of elemental iron of 50mg / mL is administered (dropper of 1ml = 20 drops)
Sponsors
ABL PHARMA PERU,
Eligibility
Inclusion criteria
Inclusion criteria: 1. Acceptance by the parents or legal guardians of the child documented with signing the corresponding informed consent form. 2. Have an age between 6 months and 2 years 3. Hemoglobin> 8 and <11 g / dl and / or decreased serum Ferritin. 4. Have the possibility of attending the consultation according to the schedule of study. 5. Be included between the percentiles 10-90, age-statural for age and sex according to the tables of the NCHS.
Exclusion criteria
Exclusion criteria: 1. History of intolerance to iron salts 2. History of chronic anemia resistant to treatment 3. Acute pathologies (e.g., acute infections) or chronic diseases (e.g. intestinal absorption) that can modify the blood values 4. Intestinal parasitic diseases detected by simple parasitological examination at the beginning of the study. 5. Need to use drugs that can modify the hematological values (e.g., prolonged use of AMEs, steroids in the last 3 months, cytostatics) 6. History of blood dyscracies 7. History of liver or kidney pathology
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Percentage of patients who are withdrawn from the study due to adverse reactions. Measure:Percentage of patients who are withdrawn from the study due to adverse reactions. Timepoints:12 weeks | — |
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Percentage of patients who complete their participation twelve weeks after the start of the study Measure:Percentage of patients who complete their participation twelve weeks after the start of the study Timepoints:12 weeks | — |
Countries
Peru
Outcome results
None listed